The US FDA expanded baricitinib labeling to severe alopecia areata in patients aged ≥12 years, creating an on-label systemic option for adolescents previously managed off-label.
|Articles|May 22, 2007
AUA: Pubovaginal Sling Tops Burch Colposuspension for Stress Incontinence
ANAHEIM -- The pubovaginal sling fashioned from autologous fascia outperformed Burch colposuspension for stress urinary incontinence but at a cost of a higher rate of adverse events.
Advertisement
ANAHEIM, May 22 -- The pubovaginal sling fashioned from autologous fascia outperformed Burch colposuspension for stress urinary incontinence but at a cost of a higher rate of adverse events.
Two years after surgery, the overall success rate was 47% for sling procedures and 38% for Burch colposuspension (P=0.01). Stress-specific success rates were 66% with slings and 49% for Burch procedures (P
The distribution of time to return of normal voiding differed significantly and favored Burch colposuspension (P
Advertisement
Related to this article
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5